Eligible patients were randomly assigned ( @:@ ) , stratified by baseline characteristics , to either low-dose eplerenone ( @ mg/day ) or placebo , with continuation of standard antihypertensive treatment to attain therapeutic goals ( < @/@ mm Hg ) for @ weeks .